Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent High Grade Ovarian Serous Adenocarcinoma”

31 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 31 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT04739800
What this trial is testing

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Who this might be right for
Fallopian Tube Mucinous AdenocarcinomaOvarian Seromucinous CarcinomaPlatinum-Refractory Fallopian Tube Carcinoma+47 more
National Cancer Institute (NCI) 120
Testing effectiveness (Phase 2)Ended earlyNCT03610490
What this trial is testing

Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma

Who this might be right for
Malignant Solid NeoplasmMetastatic Colorectal AdenocarcinomaMetastatic Ovarian Carcinoma+9 more
M.D. Anderson Cancer Center 16
Testing effectiveness (Phase 2)WithdrawnNCT06393751
What this trial is testing

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

Who this might be right for
Platinum-Refractory Fallopian Tube CarcinomaPlatinum-Refractory Ovarian CarcinomaPlatinum-Refractory Primary Peritoneal Carcinoma+20 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Active Not RecruitingNCT05114421
What this trial is testing

Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients

Who this might be right for
High Grade Fallopian Tube Serous AdenocarcinomaHigh Grade Ovarian Serous AdenocarcinomaPeritoneal High Grade Serous Adenocarcinoma+3 more
M.D. Anderson Cancer Center 30
Large-scale testing (Phase 3)Ended earlyNCT04729608
What this trial is testing

Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Who this might be right for
Platinum-resistant Ovarian Cancer
Aravive, Inc. 366
Testing effectiveness (Phase 2)Study completedNCT03648489
What this trial is testing

Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)

Who this might be right for
Ovarian CancerOvarian NeoplasmsOvarian Carcinosarcoma+7 more
Imperial College London 134
Testing effectiveness (Phase 2)Active Not RecruitingNCT03907852
What this trial is testing

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

Who this might be right for
MesotheliomaMesothelioma, MalignantMesothelioma; Pleura+8 more
TCR2 Therapeutics 57
Early research (Phase 1)Looking for participantsNCT05039801
What this trial is testing

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Who this might be right for
Advanced Endometrial CarcinomaAdvanced Head and Neck Squamous Cell CarcinomaAdvanced Malignant Solid Neoplasm+35 more
M.D. Anderson Cancer Center 54
Testing effectiveness (Phase 2)WithdrawnNCT02756130
What this trial is testing

Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC)

Who this might be right for
High Grade Fallopian Tube Serous AdenocarcinomaHigh Grade Ovarian Serous AdenocarcinomaPrimary Peritoneal High Grade Serous Adenocarcinoma+3 more
Jonsson Comprehensive Cancer Center
Early research (Phase 1)Ended earlyNCT03924245
What this trial is testing

Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers

Who this might be right for
Fallopian Tube CancerFallopian Tube CarcinosarcomaFallopian Tube Clear Cell Adenocarcinoma+10 more
Vanderbilt-Ingram Cancer Center 3
Testing effectiveness (Phase 2)Active Not RecruitingNCT05920798
What this trial is testing

Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Who this might be right for
Fallopian Tube CarcinosarcomaPrimary Peritoneal CarcinosarcomaRecurrent Fallopian Tube Carcinoma+13 more
Mayo Clinic 38
Early research (Phase 1)Active Not RecruitingNCT02208375
What this trial is testing

MTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

Who this might be right for
BRCA1 Mutation CarrierBRCA2 Mutation CarrierEndometrial Adenocarcinoma+13 more
M.D. Anderson Cancer Center 159
Testing effectiveness (Phase 2)Active Not RecruitingNCT01116648
What this trial is testing

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

Who this might be right for
Fallopian Tube CarcinomaOvarian Endometrioid AdenocarcinomaOvarian High Grade Serous Adenocarcinoma+4 more
National Cancer Institute (NCI) 155
Early research (Phase 1)Looking for participantsNCT04633239
What this trial is testing

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

Who this might be right for
Recurrent Ovarian High Grade Serous AdenocarcinomaRecurrent Platinum-Resistant Ovarian Carcinoma
National Cancer Institute (NCI) 42
Not applicableEnded earlyNCT05891197
What this trial is testing

A Biomarker Screening Protocol for Participants With Solid Tumors

Who this might be right for
Triple Negative Breast CancerNon-small Cell Lung CancerNon Small Cell Lung Cancer+19 more
Lyell Immunopharma, Inc. 10
Testing effectiveness (Phase 2)Study completedNCT03462342
What this trial is testing

Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer

Who this might be right for
High Grade Serous Carcinoma
University of Pennsylvania 123
Testing effectiveness (Phase 2)WithdrawnNCT05295589
What this trial is testing

Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy

Who this might be right for
Platinum-Refractory Fallopian Tube CarcinomaPlatinum-Refractory Ovarian CarcinomaPlatinum-Refractory Primary Peritoneal Carcinoma+9 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)UnknownNCT03509246
What this trial is testing

Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients

Who this might be right for
Ovarian Neoplasm EpithelialHigh Grade Serous Carcinoma
Seoul National University Hospital 44
Early research (Phase 1)Looking for participantsNCT05950464
What this trial is testing

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

Who this might be right for
Recurrent Endometrial CarcinomaRecurrent Endometrial Clear Cell AdenocarcinomaRecurrent Endometrial Endometrioid Adenocarcinoma+6 more
National Cancer Institute (NCI) 65
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07504588
What this trial is testing

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

Who this might be right for
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid AdenocarcinomaRecurrent Platinum-Sensitive Fallopian Tube High Grade Serous AdenocarcinomaRecurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma+3 more
National Cancer Institute (NCI)
Next Page
87